BR0317909A - Stent, método para a fabricação de um stent, método para tratar ou evitar uma doença, método para tratar ou prevenir aterosclerose em um paciente, e, conjunto - Google Patents

Stent, método para a fabricação de um stent, método para tratar ou evitar uma doença, método para tratar ou prevenir aterosclerose em um paciente, e, conjunto

Info

Publication number
BR0317909A
BR0317909A BR0317909-5A BR0317909A BR0317909A BR 0317909 A BR0317909 A BR 0317909A BR 0317909 A BR0317909 A BR 0317909A BR 0317909 A BR0317909 A BR 0317909A
Authority
BR
Brazil
Prior art keywords
stent
treating
preventing
patient
disease
Prior art date
Application number
BR0317909-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Jerome B Zeldis
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of BR0317909A publication Critical patent/BR0317909A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A61F2/07—Stent-grafts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/434—Inhibitors, antagonists of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
BR0317909-5A 2002-12-31 2003-12-31 Stent, método para a fabricação de um stent, método para tratar ou evitar uma doença, método para tratar ou prevenir aterosclerose em um paciente, e, conjunto BR0317909A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43733202P 2002-12-31 2002-12-31
US10/749,344 US20050019366A1 (en) 2002-12-31 2003-12-30 Drug-coated stents and methods of use therefor
PCT/US2003/041763 WO2004060318A2 (en) 2002-12-31 2003-12-31 Drug-coated stents and methods of use therefor

Publications (1)

Publication Number Publication Date
BR0317909A true BR0317909A (pt) 2005-11-29

Family

ID=32717896

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317909-5A BR0317909A (pt) 2002-12-31 2003-12-31 Stent, método para a fabricação de um stent, método para tratar ou evitar uma doença, método para tratar ou prevenir aterosclerose em um paciente, e, conjunto

Country Status (11)

Country Link
US (1) US20050019366A1 (enExample)
EP (1) EP1587440A4 (enExample)
JP (1) JP2006512143A (enExample)
KR (1) KR20050091047A (enExample)
AU (1) AU2003300466A1 (enExample)
BR (1) BR0317909A (enExample)
CA (1) CA2512056A1 (enExample)
IL (1) IL169440A0 (enExample)
MX (1) MXPA05006999A (enExample)
TW (1) TW200512016A (enExample)
WO (1) WO2004060318A2 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
AU2002218000A1 (en) * 2000-11-01 2002-05-15 Genomic Solutions, Inc. Compositions and systems for identifying and comparing expressed genes (mrnas) in eukaryotic organisms
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
US20070160622A1 (en) * 2005-12-07 2007-07-12 Medivas, Llc Method for assembling a polymer-biologic delivery composition
US7959659B2 (en) * 2004-01-02 2011-06-14 Advanced Cardiovascular Systems, Inc. High-density lipoprotein coated medical devices
WO2005074921A1 (en) * 2004-02-09 2005-08-18 University Of Zurich Treatment of atherosclerosis
US20060013855A1 (en) * 2004-04-05 2006-01-19 Medivas, Llc Bioactive stents for type II diabetics and methods for use thereof
US8163269B2 (en) * 2004-04-05 2012-04-24 Carpenter Kenneth W Bioactive stents for type II diabetics and methods for use thereof
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
US20060125144A1 (en) * 2004-12-14 2006-06-15 Jan Weber Stent and stent manufacturing methods
US7335697B2 (en) 2004-12-23 2008-02-26 Depuy Products, Inc. Polymer composition comprising cross-linked polyethylene and methods for making the same
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8652504B2 (en) * 2005-09-22 2014-02-18 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
EP1926780B1 (en) 2005-09-22 2013-08-14 Medivas, LLC Bis-( -amino)-diol-diester-containing poly(ester amide) and poly(ester urethane) compositions and methods of use
US8343230B2 (en) * 2005-09-22 2013-01-01 Depuy Products, Inc. Orthopaedic bearing material
US20070077268A1 (en) * 2005-09-30 2007-04-05 Depuy Products, Inc. Hydrophobic carrier modified implants for beneficial agent delivery
US7812098B2 (en) 2006-03-31 2010-10-12 Depuy Products, Inc. Bearing material of medical implant having reduced wear rate and method for reducing wear rate
US20070292476A1 (en) * 2006-05-02 2007-12-20 Medivas, Llc Delivery of ophthalmologic agents to the exterior or interior of the eye
JP5196498B2 (ja) * 2006-05-09 2013-05-15 メディバス エルエルシー 生分解性水溶性ポリマー
US20080085293A1 (en) * 2006-08-22 2008-04-10 Jenchen Yang Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
ATE481989T1 (de) 2006-08-25 2010-10-15 Depuy Products Inc Material zum tragen eines medizinischen implantats
DE102006042313A1 (de) * 2006-09-06 2008-03-27 Biotronik Vi Patent Ag Biokorrodierbares metallisches Implantat mit einer Beschichtung oder Kavitätenfüllung aus Gelatine
DE102007002717A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclische Indazolderivate
WO2008091925A2 (en) * 2007-01-23 2008-07-31 Cook Incorporated Treatment of aortic dissection or aneurysm
DE102007022565A1 (de) 2007-05-14 2008-11-20 Merck Patent Gmbh Heterocyclische Indazolderivate
WO2009015143A1 (en) * 2007-07-24 2009-01-29 Medivas, Llc Biodegradable cationic polymer gene transfer compositions and methods of use
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
EP2303841A1 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
WO2010009155A2 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Fused heterocyclyc inhibitor compounds
WO2010009139A2 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Imidazolyl pyrimidine inhibitor compounds
MX2011001090A (es) 2008-07-28 2011-03-15 Gilead Sciences Inc Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno.
WO2010019716A1 (en) * 2008-08-13 2010-02-18 Medivas, Llc Aabb-poly(depsipeptide) biodegradable polymers and methods of use
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
DE102008042603A1 (de) * 2008-10-06 2010-04-08 Biotronik Vi Patent Ag Implantat sowie Verfahren zur Herstellung einer degradationshemmenden Schicht auf einer Körperoberfläche eines Implantats
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
AU2010259042A1 (en) 2009-06-08 2011-12-15 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds
EP2440519A1 (en) 2009-06-08 2012-04-18 Gilead Sciences, Inc. Alkanoylamino benzamide aniline hdac inihibitor compounds
US8486013B2 (en) * 2010-03-18 2013-07-16 Biotronik Ag Balloon catheter having coating
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
CA2839526A1 (en) 2011-06-23 2012-12-27 Dsm Ip Assets B.V. Micro- or nanoparticles comprising a biodegradable polyesteramide copolymer for use in the delivery of bioactive agents
WO2013091670A1 (en) * 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
AU2014301631A1 (en) 2013-06-26 2015-08-27 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
EP3233067B1 (en) 2014-12-18 2019-11-06 DSM IP Assets B.V. Drug delivery system for delivery of acid sensitive drugs
US10065018B2 (en) 2016-03-16 2018-09-04 Krishna Rocha-Singh Apparatus and method for promoting angiogenesis in ischemic tissue
US10610669B2 (en) 2016-03-16 2020-04-07 Krishna Rocha-Singh, M.D. Apparatus and method for promoting angiogenesis in ischemic tissue

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3095415A (en) * 1958-05-30 1963-06-25 Ciba Ltd Anthraquinone dyestuffs containing a 2-chloro, 4-hydroxy (lower) alkylamino, triazinylamino group
CH428043A (fr) * 1965-08-16 1967-01-15 Sandoz Ag Procédé de fabrication de colorants de dispersion isothiazolantroniques
US3541110A (en) * 1967-01-20 1970-11-17 American Home Prod Indazole-5-sulfonamides
JPS63184364A (ja) * 1987-01-27 1988-07-29 Toshiba Corp 半導体装置の製造方法
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
DE69630798T2 (de) * 1995-09-19 2004-09-23 Fujisawa Pharmaceutical Co., Ltd. Aerosolzusammensetzungen
AP1147A (en) * 1996-05-03 2003-02-25 Pfizer Substituted indazole derivatives and related compounds.
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
JP2001518094A (ja) * 1997-03-31 2001-10-09 デュポン ファーマシューティカルズ カンパニー Ｈｉｖプロテアーゼ阻害剤として有用なインダゾール−環式尿素
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US20020188037A1 (en) * 1999-04-15 2002-12-12 Chudzik Stephen J. Method and system for providing bioactive agent release coating
US6206835B1 (en) * 1999-03-24 2001-03-27 The B. F. Goodrich Company Remotely interrogated diagnostic implant device with electrically passive sensor
CN1304375C (zh) * 1999-08-19 2007-03-14 信号药品公司 用作jnk抑制剂的吡唑并蒽酮及其衍生物和它们的组合物
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
CA2369076A1 (en) * 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
CZ20013540A3 (cs) * 2000-02-05 2002-03-13 Vertex Pharmaceuticals Incorporated Deriváty pyrazolu jako inhibitory ERK a farmaceutický prostředek, který je obsahuje
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US6987184B2 (en) * 2001-02-15 2006-01-17 Signal Pharmaceuticals, Llc Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related
CN1300116C (zh) * 2001-04-16 2007-02-14 卫材株式会社 1h－吲唑化合物
AUPS078002A0 (en) * 2002-02-27 2002-03-21 Unisearch Limited Dnazyme therapeutics

Also Published As

Publication number Publication date
CA2512056A1 (en) 2004-07-22
WO2004060318A2 (en) 2004-07-22
TW200512016A (en) 2005-04-01
US20050019366A1 (en) 2005-01-27
IL169440A0 (en) 2007-07-04
KR20050091047A (ko) 2005-09-14
EP1587440A4 (en) 2006-08-02
AU2003300466A1 (en) 2004-07-29
WO2004060318A3 (en) 2004-10-21
JP2006512143A (ja) 2006-04-13
MXPA05006999A (es) 2005-08-18
EP1587440A2 (en) 2005-10-26

Similar Documents

Publication Publication Date Title
BR0317909A (pt) Stent, método para a fabricação de um stent, método para tratar ou evitar uma doença, método para tratar ou prevenir aterosclerose em um paciente, e, conjunto
BR0213279A (pt) Revestimento de stents para impedir a restenose
BRPI0717438B8 (pt) método para produzir um stent endovascular radialmente expansível e stent endovascular radialmente expandível
MX2007000350A (es) Stent con elementos asimetricos de longitud desigual.
WO2006044509A3 (en) Methods of treating vascular injuries
TW200603838A (en) Extended release biodegradable ocular implants
EP1389472A3 (de) Endovaskuläres Implantat mit aktiver Beschichtung
WO2006024488A3 (en) Medical stent provided with inhibitors of atp synthesis
WO2005092244A3 (en) Stent system for preventing restenosis
BRPI0519805B8 (pt) implante dental estreito e partes associadas
DE60325578D1 (de) Vorrichtung zur vollständigen sicherung eines stents
WO2004069201A3 (en) Compounds useful in coating stents to prevent and treat stenosis and restenosis
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
NO20044459L (no) Anvendelse av IL-18-inhibitorer for behandlingen og/eller forebyggingen av perifere vaskulaere sykdomrner
DE602007012273D1 (de) Vorrichtung zum in-situ-embolieschutz
WO2009017863A3 (en) Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
MXPA05011620A (es) Dispositivos medicos y metodos para inhibir la proliferacion de celulas de musculo liso.
MY159075A (en) Modified lecithin-cholesterol acyltransferase enzymes
ATE522215T1 (de) Verwendung von 3,11b-cis-dihydrotetrabenazine zur behandlung von symptomen von huntington-chorea
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
NO20030579D0 (no) Vaskul¶re grafter og fremgangsmåter til implantering derav
FR2872431B1 (fr) Utilisation de fibroplastes gingivaux en therapie cellulaire vasculaire
WO2010042343A3 (en) Combination local delivery using a stent
WO2003059192A3 (en) C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis
NZ519722A (en) Treatment of diabetic ulcers

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.